AIM
XFOR icon

Alambic Investment Management’s X4 Pharmaceuticals XFOR Stock Holding History

Alambic Investment Management’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-743
Closed -$217K – 381
2018
Q3 		$217K Buy
743
+676
+1,009% +$287K 0.17% 201
2018
Q2 		$44K Buy
+67
New +$219K 0.01% 347

Other funds holding XFOR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alambic Investment Management's XFOR Position: Q4 2018 in Review

Alambic Investment Management sold out of X4 Pharmaceuticals (XFOR) in Q4 2018, closing a stake of 743 shares — an estimated $217K sold.

Alambic Investment Management first reported a position in XFOR in Q2 2018 and held it in 2 quarters. The position peaked at $217K in Q3 2018. 36 funds tracked by Wall St. Rank hold XFOR as of Q4 2018.

  • Alambic Investment Management reported no remaining X4 Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Alambic Investment Management sold 743 X4 Pharmaceuticals shares in Q4 2018, an estimated $217K.
  • Alambic Investment Management first reported a position in X4 Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • Alambic Investment Management's X4 Pharmaceuticals position peaked at $217K in Q3 2018.
  • 36 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q4 2018.

Based on Alambic Investment Management's 13F filing for Q4 2018, filed 12 Feb 2019.